Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiodesixBDSX +1.68%52 3-Year EBITDA Growth Rate is 50.80% as of Jun. 2026, which is 15% above its 10-year median of 44.20. GuruFocus rates BDSX with a GF Score™ of 52/100 and a GF Value™ of $21.13 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Biodesix ranks better than 84.43% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 50.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 48.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Biodesix was 52.80% per year. The lowest was -30.90% per year. And the median was 44.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Biodesix 3-Year EBITDA Growth Rate Related Terms
BDSX vs MYGN, XGN, IMDX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Biodesix's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biodesix 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biodesix's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Biodesix's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 50.80% mean?
Biodesix (BDSX) has a 3-Year EBITDA Growth Rate of 50.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biodesix and its competitors. This is 15% above median its historical median of 44.20. According to the industry distribution chart, Biodesix ranks #26 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 15.6%.
Is Biodesix's 3-Year EBITDA Growth Rate too high?
Biodesix's current 3-Year EBITDA Growth Rate of 50.80% is 15% above median its 10-year median of 44.20. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. Biodesix's value of 50.80% is 361.8% above this industry median. Based on the distribution chart, Biodesix ranks #26 out of 167 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Biodesix has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biodesix's 3-Year EBITDA Growth Rate compare to MYGN and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Biodesix ranks #26 out of 167 companies for 3-Year EBITDA Growth Rate. This places Biodesix in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.00. Biodesix's value of 50.80% is 361.8% above this benchmark. While the company's 10-year median is 44.20 vs. the industry median of 11.00, Biodesix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biodesix's current 3-Year EBITDA Growth Rate of 50.80% is 361.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biodesix and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biodesix's current 3-Year EBITDA Growth Rate is 50.80%, which is 15% above median its own 10-year median of 44.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodesix stock overvalued right now?
Based on GuruFocus' analysis, Biodesix (BDSX) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.13, compared to a current price of $26.87 — trading 27.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 50.80%, which is 15% above median its 10-year median of 44.20 and 361.8% above the Medical Diagnostics & Research industry median of 11.00. Biodesix's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Biodesix (BDSX), the current 3-Year EBITDA Growth Rate is 50.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biodesix (BDSX) Overvalued in 2026?
Based on GuruFocus' analysis, Biodesix stock appears to be overvalued.
The current stock price of $26.87 is trading 27.2% above its estimated GF Value™ of $21.13.
GuruFocus considers Biodesix to be Modestly Overvalued.
Key valuation signals for BDSX:
3-Year EBITDA Growth Rate: 50.80% (15% above median its 10-year median of 44.20)
GF Value™: $21.13 vs. price of $26.87 (27.2% above fair value)
Industry Position: 361.8% above the Medical Diagnostics & Research median (#26 of 167)
No single metric tells the full story. See the BDSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
52GF Score
Get the complete analysis for BDSX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BDSX has been successfully added to your 
